Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | February 07, 2017 | February 10, 2017 |
| Harvard Apparatus Regenerative Technology, Inc.HRGN · Entity 7501 | Director | June 27, 2025 | July 01, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date February 07, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 925,571 |
Reported balance
After 2017-02-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-02-07 · Sale · Disposed 3,239 · Balance 925,571 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2016. F2: Includes (a) a deferred stock award of 12,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 887,671 shares of common stock held by the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectDavid Green 2015-1 Annuity Trust | 234,896 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 234,896 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2016.
F2: Includes (a) a deferred stock award of 12,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 887,671 shares of common stock held by the Reporting Person.
Harvard Apparatus Regenerative Technology, Inc.
Report date June 27, 2025 · Filed July 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2035-06-27 | Direct | 18,590 |
Reported balance
After 2025-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-27 · Grant · Acquired 18,590 · Balance 18,590 F1: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2035-06-27 | Direct | 15,227 |
Reported balance
After 2025-06-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-27 · Grant · Acquired 15,227 · Balance 15,227 F2: This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.
F2: This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2025 Filed Jul 1, 2025 13:57 UTC | Harvard Apparatus Regenerative Technology, Inc. HRGN · Entity 7501 | GrantStock Option (right to buy) · Derivative | 15,227 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001437749-25-021704 · rdgdoc.xml · derivative · entry 2 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,227 Underlying: Common Stock, par value $0.01 per share · 15,227 shares Expires 2035-06-27 F2 · derivative.exercise_date: This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 13:57 UTC | Harvard Apparatus Regenerative Technology, Inc. HRGN · Entity 7501 | GrantStock Option (right to buy) · Derivative | 18,590 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001437749-25-021704 · rdgdoc.xml · derivative · entry 1 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,590 Underlying: Common Stock, par value $0.01 per share · 18,590 shares Expires 2035-06-27 F1 · derivative.exercise_date: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. Read SEC document |
| June 27, 2024 Filed Jul 15, 2024 11:09 UTC | Harvard Apparatus Regenerative Technology, Inc. HRGN · Entity 7501 | GrantStock Option (right to buy) · Derivative | 8,215 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001493152-24-027251 · ownership.xml · derivative · entry 2 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,215 Underlying: Common Stock, par value $0.01 per share · 8,215 shares Expires 2034-06-27 F2 · derivative.exercise_date: This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. Read SEC document |
| June 27, 2024 Filed Jul 15, 2024 11:09 UTC | Harvard Apparatus Regenerative Technology, Inc. HRGN · Entity 7501 | GrantStock Option (right to buy) · Derivative | 10,204 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001493152-24-027251 · ownership.xml · derivative · entry 1 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,204 Underlying: Common Stock, par value $0.01 per share · 10,204 shares Expires 2034-06-27 F1 · derivative.exercise_date: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 16:00 UTC | Harvard Apparatus Regenerative Technology, Inc. HRGN · Entity 7501 | GrantStock Option (right to buy) · Derivative | 5,819 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001493152-23-025853 · ownership.xml · derivative · entry 2 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,819 Underlying: Common Stock, par value $0.01 per share · 5,819 shares Expires 2033-07-26 F2 · derivative.exercise_date: This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, September 30, 2023, December 31, 2023 and March 31, 2024. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 16:00 UTC | Harvard Apparatus Regenerative Technology, Inc. HRGN · Entity 7501 | GrantStock Option (right to buy) · Derivative | 7,269 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001493152-23-025853 · ownership.xml · derivative · entry 1 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,269 Underlying: Common Stock, par value $0.01 per share · 7,269 shares Expires 2033-07-26 F1 · derivative.exercise_date: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on October 26, 2023, January 26, 2024, April 26, 2024 and July 26, 2024. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 20:00 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 732,384 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-23-006611 · ownership.xml · derivative · entry 3 GREEN DAVID · CIK 0001008643 · Director · CEO as of 2/28/2023 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,384 Underlying: Common Stock, par value $0.01 per share · 732,384 shares Expires 2033-02-28 F3 · derivative.exercise_date: The non-qualified stock option was scheduled to vest monthly in thirty-six equal monthly installments on each monthly anniversary of February 28, 2023, but in connection with the Issuer's transition to a new CEO as of March 1, 2023, 488,256 shares underlying this option have been forfeited, and subject to the Reporting Person's execution of a customary release, the remaining 244,128 shares will be deemed fully vested and exercisable. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 20:00 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 38,773 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-23-006611 · ownership.xml · derivative · entry 2 GREEN DAVID · CIK 0001008643 · Director · CEO as of 2/28/2023 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,773 Underlying: Common Stock, par value $0.01 per share · 38,773 shares Expires 2033-02-28 F2 · derivative.exercise_date: The non-qualified stock option was scheduled to vest during the twelve months following the grant date, but in connection with the Issuer's transition to a new CEO as of March 1, 2023, this option has been forfeited. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 20:00 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 39,662 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-23-006611 · ownership.xml · derivative · entry 1 GREEN DAVID · CIK 0001008643 · Director · CEO as of 2/28/2023 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,662 Underlying: Common Stock, par value $0.01 per share · 39,662 shares Expires 2033-02-28 F1 · derivative.exercise_date: This stock option grant was fully exercisable as of date of grant. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 10:52 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 47,651 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001415889-23-001502 · form4-01272023_030146.xml · derivative · entry 1 GREEN DAVID · CIK 0001008643 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,651 Underlying: Common Stock, par value $0.01 per share · 47,651 shares Expires 2033-01-25 F1 · derivative.exercise_date: Subject to continued employment through the applicable vesting dates, the non-qualified stock option will vest monthly in twelve equal monthly installments on each monthly anniversary of January 25, 2023. Read SEC document |
| May 12, 2022 Filed May 23, 2022 14:45 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | PurchaseWarrants (right to buy) · Derivative | 31,673 | Not disclosed Strike: $8.88 | Not disclosed |
DisclosureSEC source: 0001104659-22-063797 · tm2216578-1_4seq1.xml · derivative · entry 3 GREEN DAVID · CIK 0001008643 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,673 Underlying: Common Stock · 31,673 shares Expires 2027-05-12 F1 · kind: On May 12, 2022, the Issuer and the Reporting Person entered into 2 securities purchase agreements (the "Purchase Agreement") pursuant to which the Reporting Person acquired from the Issuer in a private placement: (i) 63,345 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 31,673 shares of common stock with an exercise price of $8.88 per share (the "Warrants"). The aggregate subscription amount paid by the Reporting Person for the Shares and Warrants acquired by it pursuant to the Purchase Agreements was $375,000. F1 · price: On May 12, 2022, the Issuer and the Reporting Person entered into 2 securities purchase agreements (the "Purchase Agreement") pursuant to which the Reporting Person acquired from the Issuer in a private placement: (i) 63,345 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 31,673 shares of common stock with an exercise price of $8.88 per share (the "Warrants"). The aggregate subscription amount paid by the Reporting Person for the Shares and Warrants acquired by it pursuant to the Purchase Agreements was $375,000. Read SEC document |
| May 12, 2022 Filed May 23, 2022 14:45 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | PurchaseCommon Stock | 63,345 | $5.92 | $375,002.40 |
DisclosureSEC source: 0001104659-22-063797 · tm2216578-1_4seq1.xml · nonDerivative · entry 1 GREEN DAVID · CIK 0001008643 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,861 F1 · price: On May 12, 2022, the Issuer and the Reporting Person entered into 2 securities purchase agreements (the "Purchase Agreement") pursuant to which the Reporting Person acquired from the Issuer in a private placement: (i) 63,345 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 31,673 shares of common stock with an exercise price of $8.88 per share (the "Warrants"). The aggregate subscription amount paid by the Reporting Person for the Shares and Warrants acquired by it pursuant to the Purchase Agreements was $375,000. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 18:14 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 374,094 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-21-145061 · tm2134262d2_4seq1.xml · derivative · entry 4 GREEN DAVID · CIK 0001008643 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,094 Underlying: Common Stock, par value $0.01 per share · 374,094 shares Expires 2031-11-26 F2 · derivative.exercise_date: Subject to continued employment or service through the applicable vesting dates, (i) 106,884 shares will vest monthly in twelve equal monthly installments on each monthly anniversary of November 26, 2021, and (ii) up to 267,210 shall vest in three increments, two for 80,163 shares each and the third for 106,884 shares, each such vesting subject to certain performance milestones set by the Board of Directors of the Issuer. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 18:14 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | PurchaseWarrant (right to buy) · Derivative | 36,232 | Not disclosed Strike: $3.45 | Not disclosed |
DisclosureSEC source: 0001104659-21-145061 · tm2134262d2_4seq1.xml · derivative · entry 3 GREEN DAVID · CIK 0001008643 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,232 Underlying: Common Stock, par value $0.01 per share · 36,232 shares Expires 2026-11-26 F1 · kind: On November 26, 2021, the Issuer and the Reporting Person entered into a securities purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired from the Issuer in a private placement: (i) 72,464 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) a warrant to purchase up to 36,232 shares of common stock with an exercise price of $2.00 per share (the "Warrant"). The aggregate subscription amount paid by the Reporting Person for the Shares and Warrant acquired by it pursuant to the Purchase Agreement was $250,000. F1 · price: On November 26, 2021, the Issuer and the Reporting Person entered into a securities purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired from the Issuer in a private placement: (i) 72,464 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) a warrant to purchase up to 36,232 shares of common stock with an exercise price of $2.00 per share (the "Warrant"). The aggregate subscription amount paid by the Reporting Person for the Shares and Warrant acquired by it pursuant to the Purchase Agreement was $250,000. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 18:14 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | PurchaseCommon Stock | 72,464 | $3.45 | $250,000.80 |
DisclosureSEC source: 0001104659-21-145061 · tm2134262d2_4seq1.xml · nonDerivative · entry 1 GREEN DAVID · CIK 0001008643 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,516 F1 · price: On November 26, 2021, the Issuer and the Reporting Person entered into a securities purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired from the Issuer in a private placement: (i) 72,464 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) a warrant to purchase up to 36,232 shares of common stock with an exercise price of $2.00 per share (the "Warrant"). The aggregate subscription amount paid by the Reporting Person for the Shares and Warrant acquired by it pursuant to the Purchase Agreement was $250,000. Read SEC document |
| February 07, 2017 Filed Feb 10, 2017 07:52 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 3,239 | $3.25 | $10,526.75 |
DisclosureSEC source: 0001209191-17-009339 · doc4.xml · nonDerivative · entry 1 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,571 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2016. F2 · balance_after: Includes (a) a deferred stock award of 12,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 887,671 shares of common stock held by the Reporting Person. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 16:11 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 1,288 | $3.25 | $4,186.00 |
DisclosureSEC source: 0001209191-17-008304 · doc4.xml · nonDerivative · entry 1 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,810 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2016. F2 · balance_after: Includes (a) a deferred stock award of 12,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 890,910 shares of common stock held by the Reporting Person. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 16:41 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 12,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000998 · doc4.xml · nonDerivative · entry 1 GREEN DAVID · CIK 0001008643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,810 F1 · shares: Represents a deferred stock award of 12,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2017. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 12,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 504,910 shares of common stock held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.